Key result
Recombinant Aminopeptidase A cleaves multiple angiotensin peptides and attenuates the pressor activities of infused Ang I and Ang II, but not Ang-(1-12).
Why the study?
Because several RAS peptides contain an N-terminal aspartate, the study investigated recombinant APA's hydrolytic action across multiple angiotensin peptides and whether Ang-(1-12) pressor activity is altered by recombinant APA or genetic APA deficiency.
Comparison
Recombinant APA or genetic APA deficiency vs control conditions
Design
Preclinical laboratory study
Authors
Loading...
Suggests aminopeptidase A as target in Ang II hypertension; hypothesis-generating from animal data only.
Aminopeptidase A exhibits antihypertensive effects by rapidly degrading Ang II, suggesting therapeutic potential for Ang II-dependent hypertension, while Ang-(1-12) increases blood pressure via both Ang II-dependent and independent mechanisms.
Wysocki et al. (2025) studied Hypertension. Recombinant Aminopeptidase A (r-APA) was evaluated on Hydrolytic action on angiotensin peptides and alteration of pressor activity. Recombinant Aminopeptidase A cleaves multiple angiotensin peptides and attenuates the pressor activities of infused Ang I and Ang II, but not Ang-(1-12).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: